Literature DB >> 2737224

Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest.

L P Huyghens1, W A Buylaert, L Corne, M T Rosseel, M G Bogaert.   

Abstract

As the pharmacokinetics of a drug may be altered in haemodynamically compromised patients, the plasma concentrations and haemodynamic effects of the calcium entry blocker nimodipine have been examined in patients resuscitated after out-of-hospital cardiac arrest. In 7 patients nimodipine was infused at increasing rates up to 30 micrograms.kg-1.h-1. The plasma concentrations increased with increasing dose; at the highest dose a mean steady-state plasma concentration of 22.1 ng.ml-1 was obtained, and the mean plasma clearance was 1.41.kg-1.h-1. There were no marked changes in mean arterial blood pressure or heart rate. In 9 other patients nimodipine was given as a bolus infusion of 10 micrograms.kg-1 over 3 min, followed by a continuous infusion of 30 micrograms.kg-1.h-1. A mean steady-state plasma concentration of 17.6 ng.ml-1 was obtained and the mean plasma clearance was 1.91.kg-1.h-1. Heart rate did not change significantly, but the mean arterial blood pressure fell. The data indicate that in patients resuscitated after cardiac arrest, the pharmacokinetics of nimodipine are not markedly different from patients with other conditions, e.g. subarachnoid haemorrhage. However, if a loading dose is given to obtain a steady-state concentration sooner, there will be a fall in arterial blood pressure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737224     DOI: 10.1007/bf00558290

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Safety and efficacy of nimodipine in resuscitation of patients outside hospital.

Authors:  R O Roine; M Kaste; A Kinnunen; P Nikki
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-03

Review 2.  Ischaemic brain.

Authors:  N M Dearden
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

3.  Blood pressure and heart rate during treatment with nimodipine in patients with subarachnoid hemorrhage.

Authors:  D Tettenborn; J Dycka; E Volberg; P Düdden
Journal:  Neurochirurgia (Stuttg)       Date:  1985-05

Review 4.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

5.  Influence of nimodipine on cardiovascular parameters during coronary surgery.

Authors:  B von Bormann; J Boldt; D Kling; J Mulch; B Weidler; G Hempelmann
Journal:  Neurochirurgia (Stuttg)       Date:  1985-05

6.  Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage.

Authors:  E Vinge; K E Andersson; L Brandt; B Ljunggren; L G Nilsson; S Rosendal-Helgesen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Cardiovascular actions of the dihydropyridine calcium antagonist nimodipine in the dog.

Authors:  K Satoh; M Kawada; Y Wada; N Taira
Journal:  Arzneimittelforschung       Date:  1984

8.  Nimodipine improves outcome when given after complete cerebral ischemia in primates.

Authors:  P A Steen; S E Gisvold; J H Milde; L A Newberg; B W Scheithauer; W L Lanier; J D Michenfelder
Journal:  Anesthesiology       Date:  1985-04       Impact factor: 7.892

9.  Influence of cardiopulmonary resuscitation on plasma concentrations of nimodipine in the dog.

Authors:  L P Huyghens; M T Rosseel; P A Calle; W A Buylaert
Journal:  J Pharm Pharmacol       Date:  1987-12       Impact factor: 3.765

10.  Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments.

Authors:  S Kazda; B Garthoff; H P Krause; K Schlossmann
Journal:  Arzneimittelforschung       Date:  1982
View more
  1 in total

Review 1.  Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.